Zydus Lifesciences Limited has launched ANYRA™, marking a significant milestone as India's first indigenously developed biosimilar of Aflibercept 2 mg. The announcement, made on February 19, 2026, represents a major advancement in making critical ophthalmic treatments more accessible to Indian patients. The company has also entered into an agreement with Regeneron Pharmaceuticals, Inc. and Bayer to support this launch.

Product Specifications and Indications

ANYRA™ addresses multiple serious retinal conditions that can lead to vision loss if left untreated. The biosimilar is specifically indicated for several critical ophthalmic conditions:

Addressing India's Healthcare Challenge

The launch comes at a crucial time for India's healthcare landscape, where retinal diseases affect millions of patients. The country faces a substantial burden of diabetes-related eye complications and age-related vision disorders:

These conditions collectively represent a large patient pool requiring timely anti-VEGF therapy to prevent irreversible vision loss. The chronic nature of retinal diseases necessitates repeated intravitreal injections over extended periods, making affordability and treatment continuity critical concerns for patients.

Company Leadership Perspective

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, emphasized the company's commitment to accessible healthcare. He stated that ANYRA™ represents "a transformative step for affordable retinal care in India" and highlighted the company's focus on "enabling patient-centric outcomes by leveraging science, health and innovation."

Zydus Biologics Portfolio

Zydus Lifesciences maintains India's largest biosimilar portfolio, featuring more than 13 biosimilars and complex biologic molecules developed and manufactured entirely within the country. The company has established comprehensive end-to-end capabilities spanning the entire biologics development spectrum, from cell line research and process engineering to clinical trials, manufacturing, and regulatory approvals.

Company Profile

Zydus Lifesciences Limited operates as an innovation-led global life sciences company with leadership positions across pharmaceuticals and consumer wellness. The organization is supported by an emerging MedTech franchise and maintains a strong international presence across the United States, India, and other global markets. As of September 30, 2025, the group employed approximately 29,000 people worldwide, including 1,500 scientists engaged in research and development activities.

Zydus Lifesciences Limited has announced the launch of PEPAIR™, marking a significant milestone as India's first affordable Oscillating Positive Expiratory Pressure (OPEP) device. The innovative, drug-free handheld device is designed to support better respiratory health for patients suffering from chronic respiratory conditions, addressing a critical healthcare gap in the Indian market.

Product Features and Pricing

PEPAIR™ incorporates a patented design with a 3-resistance system specifically engineered to help clear congestion and support effective mucous clearance. The device aims to improve breathing in patients diagnosed with COPD, asthma, and bronchiectasis. In a patient-centric approach, the company has positioned the device at an affordable price point to ensure broader accessibility.

Market Need and Patient Impact

The launch addresses a substantial healthcare challenge, with more than 90 lakh patients suffering from chronic respiratory conditions in India. Chronic mucous hypersecretion represents a common problem among these patients, requiring effective airway clearance solutions for everyday care. OPEP-based airway clearance is recommended in established clinical guidance, but limited affordability has historically restricted access for a large proportion of patients.

Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, emphasized the company's commitment to patient-centric innovation: "At Zydus, patient-centric innovation is about advancing healthcare in ways that make everyday care more accessible for patients. With PEPAIR™, India's first affordable OPEP device, we are introducing a drug-free, handheld solution designed to support better breathing for patients with COPD, asthma and bronchiectasis."

Technology and Therapeutic Benefits

OPEP therapy utilizes a handheld, translucent device that creates pressure and vibrations during exhalation to loosen mucous, open airways, and promote clearance. PEPAIR™ contributes to clearing impaired mucociliary pathways, removing airway obstruction, reducing cough, and delivering optimal therapeutic response. The device operates without requiring any pharmaceutical intervention, making it a valuable addition to respiratory care management.

Strategic Partnership

The launch represents a collaboration between Zydus Lifesciences and AeroDel Technology Innovations Pvt. Ltd, an Indian medical device company focused on simplifying inhalation through drug-delivery and pulmonary rehabilitation. AeroDel serves as both the innovator and developer of the underlying OPEP device platform for PEPAIR™ and the manufacturing partner for the project.

Company's Respiratory Portfolio

Zydus maintains its position as one of India's largest respiratory players, supported by a comprehensive legacy in oral and inhalation therapies. The company leads the oral bronchodilator segment with Deriphyllin®, recognized among India's most prescribed methylxanthines. The respiratory portfolio spans multiple therapeutic categories:

• Inhaled Corticosteroid (ICS) + Long-Acting Beta2-Agonist (LABA) combinations
• LABA + Long-Acting Muscarinic Antagonist (LAMA) formulations
• Single Inhaler Triple Therapy (SITT) solutions
• Once-daily triple therapies including Odihale®G and Umiflo® Plus

The company pioneered several innovations in the respiratory space, including being first to introduce LABA+LAMA with Forglyn® and pioneering SITT with Forglyn® Plus.